Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 50,457 shares of the biotechnology company’s stock after selling 1,085 shares during the period. Mutual of America Capital Management LLC owned 0.05% of Sarepta Therapeutics worth $6,135,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in SRPT. Manchester Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 156 shares during the last quarter. Sunbelt Securities Inc. grew its holdings in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 232 shares during the last quarter. Huntington National Bank grew its holdings in shares of Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 175 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at $36,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SRPT has been the topic of several recent research reports. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 27th. HC Wainwright reaffirmed a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target on the stock. Finally, Guggenheim upped their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $173.52.

Sarepta Therapeutics Stock Down 5.2 %

SRPT opened at $101.22 on Tuesday. Sarepta Therapeutics, Inc. has a twelve month low of $100.14 and a twelve month high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a 50-day moving average price of $115.51 and a 200 day moving average price of $122.23. The company has a market cap of $9.67 billion, a PE ratio of 80.98 and a beta of 0.75.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.